



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/919,039	07/30/2001	Matthew R. Kaser	PA-0035 US	4191

7590 05/19/2003

Legal Department
INCYTE GENOMICS INC
3160 Porter Drive
Palo Alto, CA 94304

EXAMINER

CHAKRABARTI, ARUN K

ART UNIT

PAPER NUMBER

1634

DATE MAILED: 05/19/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.
09/919,039

Applicant(s)
Kaser

Examiner
Arun Chakrabarti

Art Unit
1634



-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.

If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.

If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.

Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).

Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) ☒ Responsive to communication(s) filed on Apr 1, 2003

2a) ☐ This action is **FINAL**.

2b) ☒ This action is non-final.

3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

Disposition of Claims

4) ☒ Claim(s) 1-21 is/are pending in the application.

4a) Of the above, claim(s) 7-11 and 15-21 is/are withdrawn from consideration.

5) ☒ Claim(s) 12-14 is/are allowed.

6) ☒ Claim(s) 1-6 is/are rejected.

7) ☐ Claim(s) is/are objected to.

8) ☐ Claims are subject to restriction and/or election requirement.

Application Papers

9) ☐ The specification is objected to by the Examiner.

10) ☐ The drawing(s) filed on is/are a) ☐ accepted or b) ☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved by the Examiner.

If approved, corrected drawings are required in reply to this Office action.

12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

13) ☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) ☐ All b) ☐ Some* c) ☐ None of:

1. ☐ Certified copies of the priority documents have been received.

2. ☐ Certified copies of the priority documents have been received in Application No. .

3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

*See the attached detailed Office action for a list of the certified copies not received.

14) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

a) ☐ The translation of the foreign language provisional application has been received.

15) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

1) ☐ Notice of References Cited (PTO-892)

4) ☐ Interview Summary (PTO-413) Paper No(s). .

2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)

5) ☐ Notice of Informal Patent Application (PTO-152)

3) ☒ Information Disclosure Statement(s) (PTO-1449) Paper No(s). 1

6) ☒ Other: Detailed Action

Art Unit: 1634

DETAILED ACTION

Election/Restriction

1. Applicant's election with traverse of Group I along with the species of SEQ ID NO: 308 and species having SEQ ID Nos: 32, 186, and 323 in Paper Nos. 0203 and 0403 respectively are acknowledged. The traversal is on the ground(s) that there is no additional burden to examine four species of nucleic acid. This is found persuasive and therefore four species of nucleic acids having SEQ ID Nos: 32, 186, 308, and 323 are hereby being examined.

LB

Claim Rejections - 35 USC § 112

2. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

3. Claims 1-6 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

Claims 1-6 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while enabled for differential expression of in vitro liver disorder created by captopril and some other drug treatment on human C3A liver cell culture only, does not reasonably provide enablement for any liver disorder of any animal. The specification does not enable any person

Art Unit: 1634

skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.

The Court in *re Wands*, 8 USPQ2d 1400 (CA FC 1988) stated with regard to enablement that

“Factors to be considered in determining whether a disclosure would require undue experimentation have been summarized by the board in *Ex parte Forman*. They include (1) the quantity of experimentation necessary, (2) the amount of direction or guidance presented, (3) the presence or absence of working examples, (4) the nature of the invention, (5) the state of the prior art, (6) the relative skill of those in the art, (7) the predictability or unpredictability of the art, and (8) the breadth of the claims.”

Here, the claim is broadly drawn to a method for identifying any liver disorder in any animal or human species. However, the specification does not provide guidance commensurate in scope with this claim, teaching only one human C3A cell culture study. The specification provides minimal guidance regarding methods for the identification of differential expression of DNA in any other liver disorder. There is only one working example of human C3A cell culture study and only a mere recitation in the specification (without any working example) that the composition is useful to diagnose a liver disorder selected from hyperlipidemia, hypertension, type II diabetes, and tumors of the liver. It is highly unpredictable whether or what other conservative variations of sequences or what other liver disorder would function. It is therefore highly unpredictable whether other sequence strategies can be identified which meets this specific criteria regarding the

Art Unit: 1634

identification of a sequence of cDNA which is differentially expressed in any liver disorder of any animal species. Further, each unknown liver disorder has unpredictable effects on differential expression of nucleic acids with variable nucleotide sequences, and no general method for a priori selection of cDNA is presented. It would require a large amount of experimentation, potentially including the synthesis of thousands of nucleic acids, in order to identify additional sequences with the claimed functionality. Given the Wand's factors opposing the full scope of enablement including the limited teaching in the specification, the presence of only one working example of human C3A cell culture study, the teaching of unpredictability in the prior art, the unpredictability of the art, the breadth of the claim, and the large amount of experimentation needed, with only the skill level in the art being neutral towards enablement, it is concluded that undue experimentation is necessary to make and use the invention as broadly claimed.

Allowable Subject Matter

4. Claims 12-14 are allowed in view of the absence of any prior art that either teaches or suggests an isolated cDNA having SEQ ID Nos:32, 186, 308, and 323.



Conclusion

5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Arun Chakrabarti, Ph. D., whose telephone number is (703)

Application/Control Number: 09/919,039

Page 5

Art Unit: 1634

306-5818. The examiner can normally be reached on 7:00 AM-4:30 PM from Monday to Friday.


If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion, can be reached on (703) 308-1119. The fax phone number for this Group is (703)746-4979.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group analyst Chantae Dessau whose telephone number is (703) 605-1237.

Arun Chakrabarti,

Patent Examiner,

April 24, 2003


ARUN K. CHAKRABARTI
PATENT EXAMINER